Summary
Objective
Aim of this study was to evaluate the cost-effectiveness of rituximab + CHOP (R-CHOP) versus CHOP alone, in Italian patients with aggressive Non-Hodgkin lymphoma (NHL), in the NHS’ perspective.
Design
The economic analysis is based on an existing Markov model which was developed to evaluate costs and effects for two hypothetical cohorts of patients aged ≥ 60 years or aged < 60 years respectively, over a time frame of 15 years after administration of chemotherapy. The model is based on five health states (start therapy, complete response, no response, progression, death) and combines efficacy data from published clinical trials (GELA-98-5) with costs of therapies and follow-up after chemotherapy, based on Italian treatment patterns. Costs and effects were discounted respectively at 6% and 1.5% per year. Extensive 1-way and Monte Carlo sensitivity analyses were conducted to test the robustness of results.
Results
For the two cohorts (age ≥ 60 or age < 60 years), incremental discounted survival gains with R-CHOP vs. CHOP were respectively 1.08 and 1.02 years per patient; incremental QALYs were 1.15 and 1.04 per patient; incremental cost/patient was €14 838 and €13 938; the incremental cost per life-year gained (cost/LYG) was therefore €13 732 and €13 717, while the incremental cost/QALY gained was €12 879 and €13 362.
Conclusions
The clinical advantage of R-CHOP is supported by values of incremental cost/LYG and cost/QALY gained, which are well below the thresholds commonly indicated both in the international and Italian literature. R-CHOP is a substantial improvement in the treatment of aggressive NHL, at a reasonable cost, in the perspective of the Italian NHS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Bibliografia
Weisemberg DD. Epidemiology of non Hodgkin’s lymphoma; recent findings regarding an emerging epidemic. Ann Oncol 1992; 5 (Suppl. 1): 19–24
Coiffier B. Non Hodgkin’s lymphomes. In: Cavalli F, Hansen HH, Kaye SB (eds). Textbook of medical oncology. London: Martin Dunitz, 1997: 265–87
Tilly H, Lepade E, Coiffier B, et al. A randomized comparison of ACVBP and CHOP in the GELA Study treatment of advanced aggressive non-Hodgkin’s lymphoma: the LNH93-5 study. Blood 2000; 96: 832a (abstr.)
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235–42
Coiffier B, Herbrecht R, Tilly H, et al. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with an analysis according to co-morbidity factors. Proc Am Soc Clin Oncol 2003a; 22: 596 (abstr. 2395)
Coiffier B, Herbrecht R, Morel CH, et al. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with an analysis according to co-morbidity factors. Hematology J 2003b; 4 (Suppl. 2): 111–2 (abstr. 0356 — EHA 2003)
Hamblin T, Best HJ, Morris J, Hornberger J. Cost-effectiveness of rituximab in treatment of diffuse large B-cell lymphoma. Abstract and poster presented at the British Society of Haematology (BSH) Conference, Brighton, April 2002
Best HJ, Hornberger J, Ommes FL, Coiffier B. Cost-effectiveness of rituximab in treatment of diffuse large B-cell lymphoma. Abstract pcn 13 and poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Arlington, May 2002. Value in Health 2002; 5(3): 198–9
Hornberger J, Lewis G. Cost-utility of rituximab in diffuse large B-cell lymphoma. Abstract presented at the EORTC (Third European Conference on the Economics of Cancer), Brussels, September 2003. Eur J Cancer 2003; 1 (Suppl. 3): S3
Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. PharmacoEconomics 1998; 13(4): 397–409
Proctor SJ, Mackie M, Dawson A, et al. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin’s disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer 2002; 38: 795–806
Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of tumors: pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer, 2001
Doorduijn J, Buijt I, Uyl-de Groot C, et al. Quality of life (QOL) in elderly patients with aggressive non-Hodgkin’s lymphoma (NHL) treated with CHOP. Blood 2001; 98(11): abstr. 1803
Ballatori E, Berto P, Roila F. L’analisi farmacoeconomica in oncologia. Roma: Il Pensiero Scientifico Editore, 1999
Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–76
Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC- C2B8 (Rituximab) anti CD20 monoclonal antibody therapy in patients with relapsed low-grade non Hodgkin’s lymphoma. Blood 1997; 90: 2188–95
Rambaldi A, Lazzari M, Manzoni C, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856–62
Spina M, Sparano JA, Jaeger U, et al. Rituximab and chemotherapy is highly effective in patients with CD20-positive non Hodgkin’s lymphoma and HIV infection. AIDS 2003; 17: 137–8
Sheldon T. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5: 1–11
Donaldson C, Currie G, Mitton C. Cost effectiveness analysis in health care: contraindications. BMJ 2002; 325: 891–4
Messori A, Trippoli S. La farmacoeconomia come disciplina scientifica: panoramica delle principali metodologie ed esempi. Giornale di Farmacoeconomia 1998; 2: 176–89
Miller MA, McCann L. Policy analysis of the use of hepatitis B, Haemophilus influenzae type B, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Econ 2000, 9: 19–35
ISTAT. Annuario Statistico Italiano. Roma: Istituto Nazionale di Statistica, 2001
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Berto, P., Morsanutto, A., Lopatriello, S. et al. Analisi costo-efficacia di rituximab + CHOP versus CHOP in soggetti affetti da linfoma non-Hodgkin aggressivo. Pharmacoeconomics-Ital-Res-Articles 6, 151–160 (2004). https://doi.org/10.1007/BF03320633
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03320633